Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia

R. Jeff Zwiener, Ricardo Uauy, Mary L. Petruska, Beverley A. Huet

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective : To determine the safety and efficacy of long-term dextran sulfate- affinity column low-density lipoprotein (LDL) apheresis for the treatment of children with receptor-negative homozygous familial hypercholesterolemia (HFH). Study design: Two children with HFH (pretreatment cholesterol levels 22.1 to 24.7 mmol/L (ranges 850 to 950 mg/dl) began LDL apheresis treatments at ages 7 and 10 years, respectively. The LDL apheresis treatment interval was generally either 7 or 14 days; for the last 2 years of the study the treatment interval was 7 days. The patients had 167 and 188 LDL apheresis procedures during 64 and 70 months, respectively. Results : Individual procedures decreased total blood cholesterol levels by 63% to 68%. When the treatment interval was 7 days, the patients' time-averaged mean total cholesterol levels decreased to 7.3 ± 0.65 mmol/L (280 ± 25 mg/dl) and 6.4 ± 0.55 mmol/L (247 ± 22 mg/dl), respectively. Both children remained clinically well with normal growth and development. There was significant regression of xanthomas in both patients. The older patient required heart surgery for preexisting aortic stenosis and coronary ostial stenosis, but neither patient had progression of hypercholesterolemia-related cardiovascular disease. With the exception of iron (deficiency in patient 1), there was no evidence of depletion of serum components. Adverse reactions to LDL apheresis were rare and never severe. Conclusions : Dextran sulfate-affinity column LDL apheresis is effective long- term treatment for children with receptor-negative HFH. (J P EDIATR 1995;126:728 35).

Original languageEnglish (US)
Pages (from-to)728-735
Number of pages8
JournalThe Journal of Pediatrics
Volume126
Issue number5
DOIs
StatePublished - 1995

Fingerprint

Hyperlipoproteinemia Type II
Blood Component Removal
LDL Lipoproteins
Dextran Sulfate
Cholesterol
Therapeutics
Xanthomatosis
Coronary Stenosis
Aortic Valve Stenosis
Hypercholesterolemia
Growth and Development
Thoracic Surgery
Cardiovascular Diseases
Iron
Safety
Serum

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. / Zwiener, R. Jeff; Uauy, Ricardo; Petruska, Mary L.; Huet, Beverley A.

In: The Journal of Pediatrics, Vol. 126, No. 5, 1995, p. 728-735.

Research output: Contribution to journalArticle

@article{26aa58c230cc48e7867226c40d0d6930,
title = "Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia",
abstract = "Objective : To determine the safety and efficacy of long-term dextran sulfate- affinity column low-density lipoprotein (LDL) apheresis for the treatment of children with receptor-negative homozygous familial hypercholesterolemia (HFH). Study design: Two children with HFH (pretreatment cholesterol levels 22.1 to 24.7 mmol/L (ranges 850 to 950 mg/dl) began LDL apheresis treatments at ages 7 and 10 years, respectively. The LDL apheresis treatment interval was generally either 7 or 14 days; for the last 2 years of the study the treatment interval was 7 days. The patients had 167 and 188 LDL apheresis procedures during 64 and 70 months, respectively. Results : Individual procedures decreased total blood cholesterol levels by 63{\%} to 68{\%}. When the treatment interval was 7 days, the patients' time-averaged mean total cholesterol levels decreased to 7.3 ± 0.65 mmol/L (280 ± 25 mg/dl) and 6.4 ± 0.55 mmol/L (247 ± 22 mg/dl), respectively. Both children remained clinically well with normal growth and development. There was significant regression of xanthomas in both patients. The older patient required heart surgery for preexisting aortic stenosis and coronary ostial stenosis, but neither patient had progression of hypercholesterolemia-related cardiovascular disease. With the exception of iron (deficiency in patient 1), there was no evidence of depletion of serum components. Adverse reactions to LDL apheresis were rare and never severe. Conclusions : Dextran sulfate-affinity column LDL apheresis is effective long- term treatment for children with receptor-negative HFH. (J P EDIATR 1995;126:728 35).",
author = "Zwiener, {R. Jeff} and Ricardo Uauy and Petruska, {Mary L.} and Huet, {Beverley A.}",
year = "1995",
doi = "10.1016/S0022-3476(95)70400-0",
language = "English (US)",
volume = "126",
pages = "728--735",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia

AU - Zwiener, R. Jeff

AU - Uauy, Ricardo

AU - Petruska, Mary L.

AU - Huet, Beverley A.

PY - 1995

Y1 - 1995

N2 - Objective : To determine the safety and efficacy of long-term dextran sulfate- affinity column low-density lipoprotein (LDL) apheresis for the treatment of children with receptor-negative homozygous familial hypercholesterolemia (HFH). Study design: Two children with HFH (pretreatment cholesterol levels 22.1 to 24.7 mmol/L (ranges 850 to 950 mg/dl) began LDL apheresis treatments at ages 7 and 10 years, respectively. The LDL apheresis treatment interval was generally either 7 or 14 days; for the last 2 years of the study the treatment interval was 7 days. The patients had 167 and 188 LDL apheresis procedures during 64 and 70 months, respectively. Results : Individual procedures decreased total blood cholesterol levels by 63% to 68%. When the treatment interval was 7 days, the patients' time-averaged mean total cholesterol levels decreased to 7.3 ± 0.65 mmol/L (280 ± 25 mg/dl) and 6.4 ± 0.55 mmol/L (247 ± 22 mg/dl), respectively. Both children remained clinically well with normal growth and development. There was significant regression of xanthomas in both patients. The older patient required heart surgery for preexisting aortic stenosis and coronary ostial stenosis, but neither patient had progression of hypercholesterolemia-related cardiovascular disease. With the exception of iron (deficiency in patient 1), there was no evidence of depletion of serum components. Adverse reactions to LDL apheresis were rare and never severe. Conclusions : Dextran sulfate-affinity column LDL apheresis is effective long- term treatment for children with receptor-negative HFH. (J P EDIATR 1995;126:728 35).

AB - Objective : To determine the safety and efficacy of long-term dextran sulfate- affinity column low-density lipoprotein (LDL) apheresis for the treatment of children with receptor-negative homozygous familial hypercholesterolemia (HFH). Study design: Two children with HFH (pretreatment cholesterol levels 22.1 to 24.7 mmol/L (ranges 850 to 950 mg/dl) began LDL apheresis treatments at ages 7 and 10 years, respectively. The LDL apheresis treatment interval was generally either 7 or 14 days; for the last 2 years of the study the treatment interval was 7 days. The patients had 167 and 188 LDL apheresis procedures during 64 and 70 months, respectively. Results : Individual procedures decreased total blood cholesterol levels by 63% to 68%. When the treatment interval was 7 days, the patients' time-averaged mean total cholesterol levels decreased to 7.3 ± 0.65 mmol/L (280 ± 25 mg/dl) and 6.4 ± 0.55 mmol/L (247 ± 22 mg/dl), respectively. Both children remained clinically well with normal growth and development. There was significant regression of xanthomas in both patients. The older patient required heart surgery for preexisting aortic stenosis and coronary ostial stenosis, but neither patient had progression of hypercholesterolemia-related cardiovascular disease. With the exception of iron (deficiency in patient 1), there was no evidence of depletion of serum components. Adverse reactions to LDL apheresis were rare and never severe. Conclusions : Dextran sulfate-affinity column LDL apheresis is effective long- term treatment for children with receptor-negative HFH. (J P EDIATR 1995;126:728 35).

UR - http://www.scopus.com/inward/record.url?scp=0029067697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029067697&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(95)70400-0

DO - 10.1016/S0022-3476(95)70400-0

M3 - Article

C2 - 7751996

AN - SCOPUS:0029067697

VL - 126

SP - 728

EP - 735

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 5

ER -